Core Viewpoint - 朝聚眼科 announced a share buyback of 120,000 shares at a cost of HKD 313,000 on November 28 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 313,000 [1] - The number of shares repurchased was 120,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 朝聚眼科醫療控股有限公司 呈交日期： 2025年11月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | 佔有關事件前的現有已發 | | | 每股發行/出 ...

Investment Rating - The report does not explicitly state an investment rating for the ophthalmology industry Core Insights - The ophthalmology medical service market in China is experiencing stable growth, with the market size projected to reach CNY 2,521.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 16.0% from 2020 to 2025 [7][10] - The revenue structure of companies in the industry is diversifying, with a notable increase in the proportion of refractive and optical services, while the basic medical sector faces pressure from policy changes and demand structure [3][50] - The overall growth rate of ophthalmology hospitals is slowing, with private hospitals expected to increase to 3,044 by 2028, while public hospitals will only expand to 83 [10][11] Company Summaries - Aier Eye Hospital continues to lead the industry with a revenue of CNY 174.84 billion, showing a 7.3% year-on-year growth, demonstrating strong risk resistance [25][29] - Huaxia Eye Hospital reported a revenue of CNY 32.7 billion, with a slight increase of 2.8% year-on-year, while its net profit rose by 3% to CNY 4.3 billion [25][26] - Puri Eye Hospital achieved a revenue of CNY 22.01 billion, with a 3.0% increase, but its net profit saw a significant drop of 66.1% due to new hospital losses and high expenses [25][30] - He Eye Hospital's revenue decreased by 1.1% to CNY 8.6 billion, but its net profit surged by 232.2% to CNY 0.54 billion, benefiting from regional business optimization [25][30] - Xima Medical reported a revenue of CNY 8.6 billion in 2025H1, a 61.29% increase year-on-year, achieving breakeven in mainland China operations [41][41] Market Dynamics - The proportion of refractive income is increasing across companies, with Puri Eye Hospital leading at 49.34%, followed by Aier Eye Hospital at 40.13% [50][47] - The cataract income share is declining, particularly for Huaxia Eye Hospital, which dropped from 22.70% to 20.15% due to the impact of centralized procurement policies [50][51] - The report highlights a trend of increasing high-end surgical procedures, which is driving up average transaction prices in the industry [58]

Core Viewpoint - The company, Chaoyue Ophthalmology (02219.HK), announced a share buyback of 120,000 shares at a cost of HKD 310,000 on November 26 [1] Group 1 - The total expenditure for the share buyback was HKD 310,000 [1] - The number of shares repurchased was 120,000 [1]

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan [1] - The company will spend HKD 308,400 to repurchase 120,000 shares [1] - The buyback is scheduled for November 26, 2025 [1]

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares at a total cost of HKD 308,400 [1] - The buyback is scheduled for November 26, 2025, reflecting a strategic move to enhance shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 | | 行股份（不包括庫存股 | 庫存股份數目 | | | | | | | 目 | | 份）數目百分比 (註3) | | | | | | 於下列日期開始時的結存(註1) | 2025年11月24日 | | 707,510,500 | | 0 | | | 707,510,500 | | 1). ...

Summary of Key Points Core Viewpoint - A total of 36 companies conducted share buybacks on November 24, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.022 million shares for a total of 636 million yuan, representing 0.825% of its total share capital for the year [1][2]. - China COSCO Shipping (01919) repurchased 3 million shares for 40.35 million yuan, accounting for 1.604% of its total share capital [2]. - China International Marine Containers (02039) repurchased 4.8904 million shares for 35.9467 million yuan, which is 1.530% of its total share capital [2]. Group 2: Other Notable Buybacks - China Feihe (06186) repurchased 7.233 million shares for 29.9668 million yuan, representing 1.969% of its total share capital [2]. - Sinopec Limited (00386) repurchased 4.054 million shares for 17.7861 million yuan, which is 0.150% of its total share capital [2]. - Pacific Basin Shipping (02343) repurchased 5 million shares for 12.757 million yuan, accounting for 1.555% of its total share capital [2]. Group 3: Smaller Buybacks - MONGOL MINING (00975) repurchased 390,000 shares for 3.6551 million yuan, which is 0.124% of its total share capital [2]. - Miniso Group (09896) repurchased 866,800 shares for 31.938 million yuan, representing 0.372% of its total share capital [2]. - Weigao Group (01066) repurchased 40,000 shares for 211,600 yuan, accounting for 4.379% of its total share capital [3].

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares at a total cost of HKD 307,800 [1] - The buyback price per share ranges from HKD 2.53 to HKD 2.58 [1]

Core Viewpoint - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 307,800 to repurchase 120,000 shares [1] - The buyback price per share ranges from HKD 2.53 to HKD 2.58 [1]